Identification of the Prognostic Factors of Stage II Colon Cancer Patients Receiving Adjuvant Chemotherapy With UFT
20 Years
80 Years
Both
Colorectal Cancer
Trial Information
Identification of the Prognostic Factors of Stage II Colon Cancer Patients Receiving Adjuvant Chemotherapy With UFT
OBJECTIVES:
- Identify the prognostic factors in patients with curatively resected stage II colon
cancer receiving adjuvant chemotherapy with tegafur-uracil.
- Identify predictive factors of chemosensitivity to this regimen in these patients.
OUTLINE: Available tumor tissue samples are analyzed by real-time reverse transcriptase-PCR
for TS, DPD, TP, OPRT, VEGF, cyclooxygenase-2, and FPGS; by PCR for microsatellite
instability and genomic deletions on chromosome arm 18q; and pathologically for tumor
budding, Crohn's-like lymphoid reaction, category of extent of poor differentiation, and
fibrotic cancer stroma. The candidate prognostic and predictive markers are analyzed for
correlation with disease-free survival, relapse-free survival, and overall survival of
patients.
Inclusion Criteria
DISEASE CHARACTERISTICS:
- Histologically confirmed adenocarcinoma of the colon or rectosigmoid
- Stage II disease
- Must be registered on clinical trial TMDU-BRI-CC-05-01
- Must have resected tumor tissue available
- No hereditary colorectal cancer
PATIENT CHARACTERISTICS:
- ECOG performance status 0-1
PRIOR CONCURRENT THERAPY:
- Not specified
Type of Study:
Observational
Study Design:
N/A
Outcome Measure:
Prognostic factors
Safety Issue:
No
Principal Investigator
Kenichi Sugihara, MD, PhD
Investigator Role:
Study Chair
Investigator Affiliation:
Tokyo Medical and Dental University
Authority:
United States: Federal Government
Study ID:
CDR0000551714
NCT ID:
NCT00898846
Start Date:
October 2006
Completion Date:
Related Keywords:
- Colorectal Cancer
- stage II colon cancer
- stage II rectal cancer
- adenocarcinoma of the colon
- adenocarcinoma of the rectum
- Colonic Neoplasms
- Colorectal Neoplasms
Name | Location |
|---|
